Wealth Enhancement Advisory Services LLC Grows Position in Stryker Corporation $SYK

Wealth Enhancement Advisory Services LLC increased its stake in shares of Stryker Corporation (NYSE:SYK) by 1.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 155,263 shares of the medical technology company’s stock after purchasing an additional 2,130 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Stryker were worth $57,790,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of SYK. Brighton Jones LLC boosted its stake in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the last quarter. Schnieders Capital Management LLC. purchased a new stake in shares of Stryker during the 2nd quarter worth approximately $205,000. Neo Ivy Capital Management bought a new position in shares of Stryker during the 2nd quarter valued at approximately $383,000. AXQ Capital LP purchased a new position in shares of Stryker in the second quarter valued at $567,000. Finally, Sfmg LLC grew its holdings in shares of Stryker by 10.1% in the second quarter. Sfmg LLC now owns 609 shares of the medical technology company’s stock valued at $241,000 after purchasing an additional 56 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Down 1.1%

Shares of NYSE:SYK opened at $335.96 on Monday. The firm has a market capitalization of $128.57 billion, a PE ratio of 39.99, a price-to-earnings-growth ratio of 1.96 and a beta of 0.85. The business has a 50 day simple moving average of $363.25 and a two-hundred day simple moving average of $365.72. Stryker Corporation has a 1 year low of $328.23 and a 1 year high of $404.87. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same period in the prior year, the business posted $4.01 earnings per share. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. On average, equities analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is 41.90%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. UBS Group decreased their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 17th. Piper Sandler restated an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. William Blair reaffirmed an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Evercore set a $390.00 price target on Stryker in a research report on Monday, January 5th. Finally, BTIG Research boosted their price objective on Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Fourteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $427.50.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 5.20% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.